Research Library — Page 121 | Reta Compare

3563 research articles. Page 121 of 143.

Articles

• Altimmune Pemvidutide: GLP-1/Glucagon Dual Focused on NASH
• Sun Pharma's Utreglutide: Long-Acting GLP-1 with Pipeline Expansion
• Zealand Pharma's Petrelintide: An Amylin Analog Paving the Way for Quad Combinations
• Gubra Pipeline: GUBamy and the Future of Amylin and Incretin-Based Therapies
• Comparing Quad-Agonists and Retatrutide in the Obesity and Metabolic Drug Pipeline
• Mechanistic Comparison of GLP-1/GIP/GCG/Amylin Quad vs. Retatrutide
• Comparing Hepatic and Metabolic Effects of Quadruple Agonists with Retatrutide
• Penta-Agonists Versus Retatrutide: A Theoretical Efficacy Comparison
• Lean Mass Preservation: Comparing Quad-Agonists to Retatrutide
• Cardiovascular Outcomes: Quad-Agonists Compared to Retatrutide
• Glycemic Control: Quad-Agonists and Retatrutide for Type 2 Diabetes
• Tolerability: Will Quad-Agonists Address GI Side Effects Seen with Retatrutide?
• Dose Convenience: Oral and Long-Acting Quad-Agonists Following Retatrutide
• Pricing and Access: Quad-Agonists in the Post-Retatrutide Landscape
• Quad-Agonist GLP Drugs for Severe Obesity: Future Perspectives
• Quad-Agonist GLP Drugs for Type 2 Diabetes and Heart Failure
• Quad-Agonist GLP Drugs for MASH/NASH: Targeting Liver Disease
• Quad-Agonist GLP Drugs for Sleep Apnea
• Quad-Agonist GLP Drugs for Polycystic Ovary Syndrome (PCOS)
• Quad-Agonist GLP Drugs for Alzheimer's and Cognitive Decline
• Exploring Quad-Agonist GLP Drugs for Addiction and Reward Pathways
• Quad-Agonist GLP Drugs for Sarcopenic Obesity in Older Adults
• Quad-Agonist GLP Drugs for Pediatric Obesity: Future Perspectives
• Quad-Agonist GLP Drugs for Chronic Kidney Disease
• Quad-Agonist GLP Drugs for Atherosclerotic Cardiovascular Disease